perftoran has been researched along with losartan potassium in 2 studies
| Studies (perftoran) | Trials (perftoran) | Recent Studies (post-2010) (perftoran) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 100 | 18 | 9 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | perftoran (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chinikov, MA; Domrachev, SA; Kurbanov, FS; Stefanov, SA; Tarichko, IuV | 1 |
| Dinikin, MS; Fadeev, RV; Feofanova, AV; Giparovich, MA; Khanevich, MD; Lisianskaia, AS; Manikhas, GM; Pshenkina, NN; Selivanov, EA; Sofronov, GA | 1 |
2 other study(ies) available for perftoran and losartan potassium
| Article | Year |
|---|---|
[One-stage esophagoplasty without transfusion of donor blood components].
Topics: Adult; Blood Loss, Surgical; Blood Substitutes; Blood Transfusion, Autologous; Erythropoietin; Esophagoplasty; Esophagus; Female; Fluorocarbons; Humans; Male; Middle Aged; Perioperative Care | 2002 |
[Features of hemocomponental therapy in oncological patients].
Topics: Adult; Anemia; Blood Component Transfusion; Blood Donors; Blood Group Antigens; Blood Group Incompatibility; Blood Loss, Surgical; Blood Substitutes; Erythropoietin; Female; Fluorocarbons; Hematinics; Histocompatibility Testing; HLA Antigens; Humans; Male; Middle Aged; Monitoring, Physiologic; Neoplasms; Quality Improvement; Recombinant Proteins; Retrospective Studies | 2011 |